PegBio Co

PegBio Co R&D Expenses

The Research & Development Expenses of PegBio Co (2565.HK) as of Nov 18, 2026 is 50.39 M CNY. In the previous year, Research & Development Expenses was 95.43 M CNY — a change of -47.20% (lower).

R&D Expenses

50.39 MCNY

YoY

-47.20%

Last updated:

Research & Development Expenses of PegBio Co is 2025 50.39 M CNY. Research & Development Expenses of PegBio Co was 2024 95.43 M CNY. It decreases by -47.20% lower compared to the previous year.

The PegBio Co R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2022
280.31 M CNY
Jan 1, 2023
236.73 M CNY
Jan 1, 2024
95.43 M CNY
Jan 1, 2025
50.39 M CNY
The PegBio Co R&D Expenses history
YEARR&D ExpensesYoY
50.39 MCNY-47.20%
95.43 MCNY-59.69%
236.73 MCNY-15.55%
280.31 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PegBio Co Stock analysis

What does PegBio Co do? PegBio Co., Ltd. generates revenue primarily through the development and commercialization of innovative drugs targeting chronic and metabolic diseases. The company's flagship product, PB-119, is a near-commercialized long-acting GLP-1 receptor agonist designed for treating type 2 diabetes and obesity. Product candidates such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309 are in development for indications including non-alcoholic steatohepatitis, opioid-induced constipation, and congenital hyperinsulinemia. The company focuses on pharmaceutical markets for chronic disease treatment, targeting patients and healthcare providers seeking advanced therapeutic solutions. PegBio's revenue streams are derived from the sale of PB-119 once it reaches commercialization, alongside potential future sales of its pipeline products. The firm targets healthcare systems and medical professionals in China, where it is headquartered, to address high-prevalence conditions like type 2 diabetes and obesity. Its product portfolio addresses unmet medical needs in metabolic disorders, positioning PegBio to capture market share in the growing biotechnology sector. The company's business model centers on developing proprietary drug candidates with strong clinical potential. PB-119, as a near-commercialized asset, is expected to drive initial revenue, while the broader pipeline of products like PB-718 and PB-2301 targets expanding therapeutic areas. PegBio aims to establish itself as a leader in chronic disease therapeutics through a focused approach on metabolic and endocrine conditions. PegBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PegBio Co stock

Research & Development Expenses of PegBio Co is 50.39 M CNY in 2025.

Research & Development Expenses of PegBio Co changed from 95.43 M CNY to 50.39 M CNY, representing a -47.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses PegBio Co since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's PegBio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — PegBio Co

All Key Metrics — PegBio Co